FDA grants priority review for Bayer's HYRNUO lung cancer application
The U.S. Food and Drug Administration has granted priority review status to Bayer's supplemental new drug application for HYRNUO (sevabertinib) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)